Skip to main content

Advertisement

SpringerLink
Log in

Prognosis in Thin Melanoma Patients: Is Slightly Less Than Excellent Still Okay?

  • ASO Perspectives
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Landow SM, Gjelsvik A, Weinstock MA. Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992–2013. J Am Acad Dermatol. 2017;76(2):258–63.

    Article  Google Scholar 

  2. Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (≤1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. J Investig Dermatol. 2015;135(4):1190–3.

    Article  CAS  Google Scholar 

  3. El Sharouni MA, Ahmed T, Varey AHR, et al. Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas. J Clin Oncol. 2021;39(11):1243–52.

    Article  Google Scholar 

  4. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Surg. 2015;102(3):148–58.

    Article  CAS  Google Scholar 

  5. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer Eighth Edition cancer staging manual. CA Cancer J Clin. 67(6): 472–492

  6. Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020;38(24):2719–27.

    Article  Google Scholar 

  7. Wong SL, Kattan MW, McMasters KM, Coit DG. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol. 2005;12(4):282–8.

    Article  Google Scholar 

  8. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. Ann Surg Oncol. 2009;16(4):941–7.

    Article  Google Scholar 

  9. Lee AY, Droppelmann N, Panageas KS, et al. Patterns and timing of initial relapse in pathologic stage II Melanoma patients. Ann Surg Oncol. 2017;24(4):939–46.

    Article  Google Scholar 

  10. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169(22):2078–86.

    Article  Google Scholar 

  11. Berrington de González A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med. 2009;169(22):2071–2077.

  12. Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019;80(1):149-157.e144.

    Article  CAS  Google Scholar 

  13. Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer. 2018;18(1):130.

    Article  Google Scholar 

  14. Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1–T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207–17.

    Article  CAS  Google Scholar 

  15. Lo SN, Scolyer RA, Thompson JF. Long-term survival of patients with thin (T1) cutaneous Melanomas: a breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol. 2018;25(4):894–902.

  16. Isaksson K, Mikiver R, Eriksson H, et al. Survival in 31 670 patients with thin melanomas: a Swedish population-based study. Br J Dermatol. 2021;184(1):60–7.

    Article  CAS  Google Scholar 

  17. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA. 2005;294(13):1647–54.

    Article  CAS  Google Scholar 

  18. Helgadottir H, Isaksson K, Fritz I, et al. Multiple primary melanoma incidence trends over five decades: a nationwide population-based study. J Natl Cancer Inst. 2021;113(3):318–28.

    Article  Google Scholar 

  19. Youlden DR, Youl PH, Soyer HP, Aitken JF, Baade PD. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma in Queensland, Australia, 1982–2010. JAMA Dermatol. 2014;150(5):526–34.

    Article  Google Scholar 

  20. Cust AE, Badcock C, Smith J, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020;182(5):1148–57.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, The Hiram C Polk Jr, MD Department of Surgery, University of Louisville, Louisville, KY, USA

    Michael E. Egger MD, MPH

Authors
  1. Michael E. Egger MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael E. Egger MD, MPH.

Ethics declarations

Conflict of interest

The author reports research support from SkylineDX and a consultancy agreement with Iovance Biotherapeutics.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Egger, M.E. Prognosis in Thin Melanoma Patients: Is Slightly Less Than Excellent Still Okay?. Ann Surg Oncol 28, 6911–6914 (2021). https://doi.org/10.1245/s10434-021-10772-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-10772-x

Search

Navigation